Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/112859
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | The multifactorial nature of Alzheimer's disease for developing potential therapeutics |
Autor: | Carreiras, M. Carmo; Mendes, Eduardo; Perry, M. Jesús; Francisco, Ana Paula; Marco-Contelles, José CSIC ORCID | Palabras clave: | oxidative stress metal chelators MAO Dual AChE/BuChE inhibitors ChEs Ca2+ dishomeostasis Aβ Alzheimer's disease |
Fecha de publicación: | 2013 | Editor: | Bentham Science Publishers | Citación: | Current Topics in Medicinal Chemistry 13: 1745-1770 (2013) | Resumen: | Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder with several target proteins contributing to its aetiology. Pathological, genetic, biochemical, and modeling studies all point to a critical role of Aβ aggregation in AD. Though there are still many enigmatic aspects of the Aβ cascade, none of the gaps invalidate the hypothesis. The amyloid hypothesis determines that the production, aggregation and accumulation of Aβ in the brain gives rise to a cascade of neurotoxic events that proceed to neuronal degeneration. Different targets of the disease include APP pathogenic cleavage, cytoskeletal destabilization, neurotransmitter and ion dyshomeostasis, metal ion accumulation, protein misfolding, oxidative stress, neuronal death and gene mutations. Thus, disease-modifying treatments for AD must interfere with the pathogenic steps responsible for the clinical symptoms: the deposition of extracellular Aβ plaques, the intracellular neurofibrillary tangles, inflammation, oxidative stress, iron deregulation, among others. The observations supporting the development of multifunctional compounds in association with the perception that several dual binding site AChEIs were able to reach different targets guided the development of a new drug design strategy, the multi-target-directed-ligand (MTDL) approach. This may be regarded as the buildup of hybrid molecules composed of distinct pharmacophores of different drugs. Thus, each pharmacophore of the new hybrid drug would preserve the capacity of interacting with their specific sites on the targets and, therefore, generate multiple specific pharmacological responses which would enable the treatment of multi-factorial diseases. This review summarizes a few current therapeutic trends on MTDL strategy intended to halt or revert the progression of the disease. © 2013 Bentham Science Publishers. | URI: | http://hdl.handle.net/10261/112859 | DOI: | 10.2174/15680266113139990135 | Identificadores: | doi: 10.2174/15680266113139990135 issn: 1568-0266 e-issn: 1873-4294 |
Aparece en las colecciones: | (IQOG) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
184
checked on 20-mar-2024
WEB OF SCIENCETM
Citations
181
checked on 27-feb-2024
Page view(s)
320
checked on 28-mar-2024
Download(s)
108
checked on 28-mar-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.